Featured Story

Alcon intraocular lens gets FDA's stringent PMA approval

Novartis' Alcon received FDA approval for its implantable AcrySof IQ ReSTOR +2.5 Diopter intraocular lens, enabling vision correction at all distances in eye care patients with or without presbyopia who undergo cataract surgery.

NHS, Oxford University in U.K. pilot study of camera-based patient monitoring

The U.K. is well known for examining healthcare costs closely and incorporating them into decision-making on spending. Now, in order to help cut healthcare costs and address a nursing shortage that is squeezing countries internationally, the government agency Innovate UK is funding a trial for a camera-based vital sign technology from startup Oxehealth.

Clinical trial finds Thoratec heart failure device better than medical management

Thoratec touted clinical trial data presented at an International Society for Heart and Lung Transplantation meeting in Nice, France, showing that advanced heart failure patients who receive ambulatory--or outpatient--care are better off using its HeartMate II left ventricular assist device than receiving optimal medical management.

NEA-backed Cartiva raises $6M after a recent FDA nod, as it heads into a PMA review

Cartiva has raised $6 million to back its musculoskeletal foot surgical products from a single investor just ahead of its first PMA review. The financing could be expanded to up to $8.5 million, according to an SEC filing. The startup has previously identified New Enterprise Associates, which has a partner on its board, as its primary investor.

EndoGastric skips toward positive study review for GERD device

EndoGastric Solutions is trumpeting promising study data for its device for gastroesophageal reflux disease, weeks after the company picked up a reimbursement code for its procedure to treat the condition.


From Our Sister Sites


Sanofi has reached out to its French neighbor Innate Pharma to collaborate on armed antibody treatments, borrowing the biotech's technology to craft new treatments for cancer and inflammatory disease.


The immuno-oncology drug Opdivo from Bristol-Myers Squibb continued on its charmed path today when the drugmaker cut short another trial for lung cancer because it had nailed its goal for overall survival. This comes after accelerated FDA approval of Opdivo for melanoma and then lung cancer, which has led analysts to keep jacking up earnings forecast, now to $7 billion in annual sales in 5 years.